// App-Quantinova.ai

743 : Pharmacokinetic and pharmacodynamic profile of a first-in-human study with MDNA11, an engineered long-acting beta-only IL-2 agonist

Researchers

Presenter

  • Minh To

Principal Investigators

  • Nina Merchant

  • Melissa Coello

  • Carole Galligan

  • Kritika Mehta

  • Victoria Atkinson

  • Martin Bexon

  • Jim Coward

  • Jenny Lee

  • Charlotte Lemech

  • Peter Lloyd

  • Jesus Antras

  • Arash Yavari

  • Fahar Merchant

Medical Centers

  • Gallipoli Medical Research Foundation, Woolloongabba, Australia

  • Chris O'Brien Lifehouse, Camperdown, Australia

  • KinDyn Consulting Ltd, Warnham, West Sussex, UK

  • Scientia Clinical Research, Randwick, NSW, Australia

  • Princess Margaret Hospital, Toronto, ON, Canada

  • ICON Cancer Care, South Brisbane, Australia

  • University of Oxford, Oxford, Germany

Locations

  • Australia

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Interleukin-2

Drug/Treatment

  • MDNA11

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Fixed Dose

  • Dose Escalation

  • First-In-Human

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved